What are the funding trends in medical imaging AI right now?

All funding deals in the medical imaging AI market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our medical imaging AI market report.

Is medical imaging AI funding slowing down this year?

Medical imaging AI funding is down this year, with fewer deals, fewer funded companies and less disclosed capital.

We counted 43 deals raising at least $716M year to date, versus 55 deals raising at least $1.0B in the same part of 2025. Deal activity is down 22%, and disclosed funding is down 31%. Funded companies fell from 53 to 41 over those comparable partial-year periods.

The biggest rounds hide a weaker market beneath them. Sirona Medical raised $40M in October 2026 and Subtle Medical raised $33M in June 2026 to support clinical deployments. Those deals are substantial, but the market still financed fewer startups overall.

Is medical imaging AI funding stronger than two years ago?

No, medical imaging AI has raised about as much disclosed money as at this point two years ago, and fewer startups are getting checks.

Year-to-date medical imaging AI capital is at least $716M, against at least $738M in the same period of 2024. The comparable 2024 period had 55 deals, against 43 now, showing a narrower current market. The median round also moved down, from $10.0M to $7.5M.

Bigger financings have not brought back the broad deal activity of 2024. In September 2024, Qure.ai completed a $65M Series D+ to expand chest imaging and other diagnostic AI internationally. In February 2025, Harrison.ai raised $112M to extend its radiology and pathology solutions into the United States. This year includes bigger individual checks, but fewer deals overall.

Has medical imaging AI already raised more than last year?

No, medical imaging AI funding this year has not yet matched the previous completed calendar year.

The year-to-date total equals 66% of the 2025 full-year funding figure and 74% of the 2024 full-year figure. By count, this year has reached 69% of the 2025 full-year deals and 64% of the 2024 full-year deals. This compares a partial year with full years on purpose: the question is whether this year has already passed an earlier one, not where it will end.

The full 2025 market recorded 62 deals and at least $1.1B, spread across diagnostic software, workflow platforms and other imaging applications. This year has not yet caught up.

Do giant deals make medical imaging AI funding look healthier?

Yes, a few giant medical imaging AI rounds make the market look stronger than most startups are experiencing, especially against 2024.

Excluding rounds above $50M, year-to-date capital was at least $411M, compared with at least $625M in the same period of 2025 and at least $561M in 2024. That means funding outside the largest checks fell 34% against 2025 and 27% against 2024, while the full total fell 31% and 3%. Excluding rounds above $100M gives the same direction: the latest total is at least $566M, down 30% against the comparable 2025 period.

The biggest checks have gone to hospital triage software, orthodontic monitoring and cardiovascular CT analysis. Most imaging AI developers are operating with far less funding.

Are $100M rounds becoming normal for medical imaging AI?

No, medical imaging AI rounds of $100M or more are still rare.

We recorded 2 disclosed rounds of $100M or more year to date, raising $250M. Only 1 round was strictly above $100M: Aidoc's $150M Series D+ in April 2026. DentalMonitoring's $100M Growth Equity financing in February 2026 sits exactly on the threshold. Laza Medical's November 2026 Series B, announced as up to $160M, has no committed amount, so it adds nothing to these figures.

The large rounds fund businesses with different buyers: hospital clinicians and orthodontists. The big checks are concentrated in specific products instead of reaching every diagnostic niche.

Are most medical imaging AI startups raising smaller rounds?

Yes, the typical medical imaging AI round is smaller than at this point in either previous year.

The current year-to-date median is $7.5M, down 7% from $8.1M at the same point in 2025 and down 25% from $10.0M at the same point in 2024. The near-term change is modest, but the two-year pattern is more significant. Large headline rounds have not pushed the typical financing back up.

Look at the smaller rounds. Among rounds with disclosed amounts, financings under $5M now account for 41% of deals, compared with 30% in the comparable 2025 period and 24% in 2024. At the same time, the $5M to under $20M bracket has become less common. A startup raising capital for a first clinical deployment may still find an initial investor, but the bigger rounds needed to expand sales look harder to get.

Are seed investors still backing medical imaging AI?

Yes, seed investors still back medical imaging AI startups, but fewer seed rounds closed than at this point last year.

We tracked 14 Seed rounds raising at least $44M year to date, compared with 20 Seed rounds and $60M at the same point in 2025. Against the same period in 2024, the Seed count is also 14, although the disclosed capital differs. Seed funding continues, but there is no surge in new rounds.

New products are still being financed. Cancilico's $2.8M Seed in January 2026 targets AI analysis of bone-marrow microscopy. TileBio's ~$2.1M Seed in March 2026 supports tissue-imaging foundation models, while Uncovr's $7M Seed in June 2026 targets surgical video workflow. The range of problems is wider than radiology report generation alone.

Are medical imaging AI startups struggling to reach Series A?

Yes, medical imaging AI startups are finding Series A funding much harder to secure this year.

The number of Series A rounds fell to 7 so far this year, from 15 at the same point in 2025 and 17 in the comparable 2024 period. This year's disclosed Series A capital is $93M, against at least $269M and at least $188M in those respective periods. Series A also now represents 16% of deals, down from 27% in the comparable 2025 period.

The companies that raised Series A show what investors will back. CARPL.ai raised a $10M Series A in July 2026 to help hospitals adopt and monitor clinical algorithms. Hypervision Surgical completed an ~$23M Series A in April 2026 for hyperspectral surgical vision. Both businesses must solve practical integration problems beyond algorithm performance.

Are mature medical imaging AI companies getting most of the money?

Yes, later-stage medical imaging AI startups are getting most of the disclosed money this year.

Among deals with a named stage, later-stage rounds accounted for 45% of year-to-date deals, against 31% in the comparable 2025 period and 37% in 2024. Those later-stage deals captured 80% of disclosed named-stage capital this year. The comparable shares were 67% and 66% in the earlier periods.

The median founding age for companies raising above $50M rose to 12 years, versus 8 years in the comparable 2025 period and 6 years in 2024. The individual financings reveal several routes to scale. Elucid's $55M Series D+ in September 2026 supported cardiovascular CT analysis. Sirona Medical financed radiology workflows, while Omniscient Neurotechnology expanded AI-derived brain mapping. Each is spending to move beyond early product development.

The table below shows this year's deal and funding mix by stage.

Stage	Deals	Capital	Capital share
Series D+	5	$294M	41%
Growth Equity	3	$127M	18%
Series A	7	$93M	13%
Series B	5	$69M+	10%
Series C	4	$67M	9%
Seed	14	$44M+	6%
Unknown	5	$21M	3%

Which kinds of medical imaging AI are getting the most money this year?

Software that measures disease and software that triages urgent cases are drawing the biggest medical imaging AI checks this year.

Quantification and measurement received $180M across 5 deals year to date, mainly DentalMonitoring's $100M Growth Equity round in February 2026 and Elucid's $55M Series D+ in September 2026. Triage and prioritization drew $156M across only 2 deals, almost all of it from Aidoc's $150M in April 2026. Detection and diagnostic AI raised at least $143M, but across 20 deals.

Scan acquisition has grown from a low base. The category received at least $54M across 3 deals, compared with $23M in the same period of 2025 and $22M in the comparable 2024 period. Vista AI's $30M Series B in January 2026 supports automated MRI scanning, while UltraSight's $24M Series B in September 2026 supports clinician guidance during cardiac ultrasound acquisition. Laza Medical's Series B, announced as structured financing of up to $160M for catheterization-lab imaging, counts as a deal with no committed amount, so the category total is a minimum.

Those large checks depend heavily on particular companies. They do not mean every startup in a category can raise big money.

The table below shows medical imaging AI categories ranked by disclosed funding this year to date.

Category	Deals	Capital	Capital share
Quantification & Measurement	5	$180M	25%
Triage & Prioritization	2	$156M	22%
Detection & Diagnostic AI	20	$143M+	20%
Imaging Workflow & Reporting	6	$74M	10%
Image Reconstruction & Enhancement	2	$55M	8%
Acquisition & Quality Optimization	3	$54M+	7%
Segmentation & Procedure Planning	3	$38M	5%
Digital Pathology AI	2	$16M	2%

Are investors losing interest in diagnostic imaging AI?

Investors still fund diagnostic imaging AI most frequently, but they now put far less money into it.

We observed 20 detection and diagnostic AI deals raising at least $143M year to date, compared with 24 deals and at least $504M in the same period of 2025. In the comparable 2024 period, the category recorded 27 deals and at least $431M. Its share of disclosed capital has dropped from 49% in the comparable 2025 period to 20% now.

The category remains active across many diseases. ScreenPoint Medical's $14M Series C in April 2026 backs breast imaging AI, Eyenuk's $5.6M Series A in June 2026 addresses eye disease screening, and Optain's $7.5M Series A in September 2026 supports retinal interpretation. These are real financings, but none resembles the large category-defining investment Harrison.ai announced in February 2025.

Can radiology workflow AI startups still raise money?

Yes, radiology workflow AI startups can still raise money, although funding has slowed this year.

Imaging workflow and reporting startups have raised $74M across 6 deals year to date, compared with at least $184M across 9 deals in the corresponding 2025 period. Their share of disclosed capital fell from 18% to 10%. The business case remains visible even while investor commitments have narrowed.

Sirona Medical's October 2026 financing announcement came with a specific claim of progress: its cloud-native radiology platform handled contracted workflows covering millions of annual scans, and the company reported strong growth in usage. CARPL.ai's $10M Series A in July 2026 supports the integration and monitoring of radiology AI applications across healthcare organizations. Incepto Medical's $16M Growth Equity round in September 2026 supports AI reporting and post-market monitoring.

Is Europe getting more medical imaging AI deals than North America?

Yes, Europe has the most medical imaging AI deals this year, and it has also raised more disclosed money than North America.

European companies completed 22 deals involving 20 companies year to date, compared with 24 deals at the same point in 2025 and 21 in 2024. Europe accounts for 51% of the current deal count. Europe also leads on disclosed capital, with at least $249M against at least $207M for North America, helped by DentalMonitoring's $100M round.

France contributes several different kinds of business. DentalMonitoring raised $100M in Growth Equity in February 2026 for AI-supported orthodontic monitoring. Incepto Medical raised $16M in Growth Equity in September 2026 to expand its medical imaging AI platform. Hypervision Surgical's ~$23M Series A in April 2026 illustrates the United Kingdom's activity in image-guided surgical tools.

Does the U.S. still lead in medical imaging AI funding?

Yes, the U.S. is still the top country for medical imaging AI funding by disclosed capital, but its total has fallen and its lead is narrow.

U.S. startups raised at least $200M across 12 deals year to date, ahead of Israel's $174M. The comparable 2025 period had 14 U.S. deals and $335M, while the corresponding 2024 period had 16 deals and at least $303M. U.S. companies now account for 28% of disclosed medical imaging AI capital and 28% of transactions.

Elucid's $55M Series D+ in September 2026, Vista AI's $30M Series B in January 2026 and Subtle Medical's $33M Series C in June 2026 show how varied American imaging AI investments are. These companies represent distinct product categories and clinical purchasing decisions.

American deal counts and capital are both weaker, and this year's two largest checks went to Israel's Aidoc and France's DentalMonitoring.

Is medical imaging AI fundraising slowing in Asia-Pacific?

Medical imaging AI fundraising in Asia-Pacific has fallen sharply against both earlier comparison periods.

The region recorded 5 deals and $86M year to date, against 12 deals and at least $261M in the same period of 2025. The comparable 2024 period had 13 deals and at least $148M. Its share of medical imaging AI transactions has fallen from 24% in the 2024 comparison window to 12% now.

The earlier periods included Qure.ai's $65M Series D+ in September 2024, led by Lightspeed and 360 ONE Asset, and Harrison.ai's $112M Series C in February 2025, which was used to accelerate international expansion. The current period includes Omniscient Neurotechnology's $27M Series D+ in May 2026 for AI brain mapping and ongoing product activity at South Korea's AIRS Medical.

Can brand-new medical imaging AI startups still get funded?

Yes, new medical imaging AI startups are still getting a first financing, although fewer did so than at this point last year.

We identified 10 first financings raising at least $57M year to date, compared with 13 financings and $86M in the equivalent 2025 period. In the same part of 2024, the comparable count was 7 first financings raising $39M. We call a round a first financing only when the source says so, and 9 deals this year have no known status. New startups are still getting funded, but fewer than at this point last year.

Several of the latest startups serve very focused clinical needs. Waiv's first round, a $33M Series A in March 2026, backs pathology-based cancer testing. Acurion's $4.3M Seed in April 2026 targets cancer imaging, and Eyedentity's ~$1.5M Seed in August 2026 targets retinal screening. Their relevance depends on the imaging content they analyze, not simply the label of general healthcare AI.

Is it harder to find investors to lead imaging AI rounds?

Yes, fewer named investors are leading medical imaging AI rounds this year.

We identified 44 unique lead investors year to date, down from 67 in the same period of 2025 and 54 in the comparable 2024 period. The share of deals with a disclosed lead also slipped to 77%, from 82% in the 2025 comparison. Both the number of known leads and the number of companies getting financed have contracted.

Credible investors still lead the earlier growth rounds. International Finance Corporation led CARPL.ai's $10M Series A in July 2026, while Heal Capital backed Hypervision Surgical's ~$23M Series A in April 2026. These deals show there are still credible lead investors at earlier growth stages.

Are hospitals becoming investors in medical imaging AI?

Sometimes, some health systems are investing in medical imaging AI, but we cannot credit them with the wider funding trend.

Vista AI's January 2026 Series B included investors associated with Cedars-Sinai, Intermountain Health and other health systems. Its company announcement described automated MRI use at hospitals and measurable improvements in appointment capacity. Sirona Medical's October 2026 funding announcement also linked its expansion to contracted imaging sites and radiologists, though its lead was Avidity Partners. CARPL.ai's July 2026 Series A was led by the International Finance Corporation and supports hospital adoption of AI tools.

In these cases, investors could point to hospital deployments and practical problems. Hospital deployments and faster workflows give these companies something tangible to show investors. We cannot measure the total invested by hospitals because the rounds do not show each investor's individual check.

Are medical imaging AI startups taking longer to raise again?

Yes, medical imaging AI startups are waiting longer between the rounds we can observe.

The median gap between tracked rounds is 25 months year to date, versus 20 months in the comparable 2025 period and 23 months in 2024. Our available history covers 63% of eligible gaps this year, compared with 56% and 67% respectively; these are gaps between rounds, not shares of all startups. The share of observed gaps shorter than 18 months is now 33%, compared with 48% in the comparable 2025 period.

Aidoc raised its $150M Series D+ in April 2026 after a $110M Series D+ in July 2025. Some established companies can still raise quickly, but the typical observed interval has lengthened.

Is medical imaging AI funding recovering quarter by quarter?

No, completed quarters show no steady recovery in medical imaging AI funding, and the latest quarter is unfinished.

Q1 2026 recorded 12 deals and at least $213M, Q2 2026 had 18 deals and $312M, and Q3 2026 had 9 deals and $142M. Q4 2026 is still partial, with 4 deals and at least $50M so far. An unfinished quarter cannot establish a recovery either way, and Laza Medical's November Series B has no committed amount.

The earlier quarters also bounced around. Q1 2025 recorded 17 deals and at least $481M, one of several quarters when a small number of large deals shaped the total. The following quarters produced different combinations of deal counts and capital.

The table below shows quarterly funding since 2024, including the incomplete current quarter.

Period	Deals	Capital	Status
Q1 2024	12	$149M	Complete
Q2 2024	16	$165M+	Complete
Q3 2024	19	$342M+	Complete
Q4 2024	17	$293M+	Complete
2024, quarter not known	3	$24M+	Year only
Q1 2025	17	$481M+	Complete
Q2 2025	15	$160M+	Complete
Q3 2025	16	$287M	Complete
Q4 2025	13	$151M	Complete
2025, quarter not known	1	Undisclosed	Year only
Q1 2026	12	$213M+	Complete
Q2 2026	18	$312M	Complete
Q3 2026	9	$142M	Complete
Q4 2026 (partial)	4	$50M+	Partial

Quarters add up to fewer deals than the yearly totals: 3 deals of 2024 and 1 of 2025 are dated only by the year, so they count in the yearly totals but in no quarter.

So, what are medical imaging AI funding trends right now?

Medical imaging AI funding is weaker this year: fewer companies raise money, Series A has thinned out, and big rounds hide some of the decline.

Year-to-date funding stands at 43 deals and at least $716M, with Aidoc's $150M round in April 2026 the largest transaction. The total is below the comparable 2025 period, while the number of funded companies and the ordinary funding pool are smaller. Total capital is about level with two years ago, on far fewer deals.

More of the funding now goes to tools that measure disease, triage urgent cases and run imaging departments. Quantitative imaging, triage, acquisition automation and enterprise software remain investable, but Seed and particularly Series A financing do not show a broad-based recovery. The current quarter is not complete, so its capital total should not be read as proof of a turnaround.

The table below shows what we found.

Question	Answer
Is this a genuine recovery for imaging AI?	No, medical imaging AI deal activity is still contracting. Deal volume fell 22% against the comparable 2025 period. The headline financing total obscures a narrower funding market.
Did more companies receive capital this year?	No, fewer distinct medical imaging AI businesses obtained funding. The count fell 23% against the same period in 2025. That matters more than a few large fundraising announcements.
Is the market stronger than two years earlier?	No, it is about level on dollars and weaker on deals. Disclosed capital is at least $716M, against at least $738M in 2024. Fewer funded deals make the market narrower.
Has this year already exceeded a full year?	No, current financing remains below the previous completed year. Capital has reached 66% of the full 2025 figure. The partial year should not be confused with a completed annual total.
Do smaller rounds indicate a wider revival?	No, the middle round has become less substantial. The median is $7.5M for the current partial year. Large rounds have not restored the earlier typical check size.
Is the slowdown limited to enormous rounds?	No, capital outside major transactions has also deteriorated. Funding excluding rounds above $50M is down 34% against 2025. Smaller issuers therefore face a weaker backdrop too.
Are nine-figure financing checks becoming routine now?	They remain exceptions despite several striking medical imaging announcements. Only 2 current deals reached $100M or more. That is not a normal funding experience for startups.
Is the Series A transition getting easier?	No, Series A activity has become much less frequent. Just 7 Series A deals closed during the current period. This constricts the route from early testing to expansion.
Do mature imaging startups receive most capital?	Yes, later-stage medical imaging companies dominate disclosed named-stage fundraising. They captured 80% of that capital during the current year. Early-stage innovators consequently compete for a much smaller pool.
Are scan acquisition companies attracting new money?	Yes, equipment-adjacent imaging AI is drawing notable commitments. UltraSight raised $24M in its September 2026 Series B. Its investment targets imaging productivity rather than detection alone.
Has medical image interpretation lost investor interest?	Not entirely, because diagnostic AI remains the busiest category. It still recorded 20 deals during the current partial year. However, investors now put larger checks into other applications.
Can the latest quarter prove a turnaround?	Not yet, because the current quarter is incomplete. Q4 2026 has recorded at least $50M in disclosed capital so far. A partial quarter cannot establish a durable recovery.